Health Catalyst (NasdaqGS:HCAT) - Share price, News & Analysis

HCAT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

HCAT Stock Overview

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations.

Rewards

Revenue is forecast to grow 15.98% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Health Catalyst Competitors

Simulations Plus

NasdaqGS:SLP

US$1.0b

Phreesia

NYSE:PHR

US$1.3b

NextGen Healthcare

NasdaqGS:NXGN

US$1.2b

Convey Health Solutions Holdings

NYSE:CNVY

US$762.0m

Price History & Performance

Summary of all time highs, changes and price drops for Health Catalyst
Historical stock prices
Current Share Price	US$15.40
52 Week High	US$59.50
52 Week Low	US$11.25
Beta	1.19
1 Month Change	9.77%
3 Month Change	-44.26%
1 Year Change	-72.83%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-60.68%

Shareholder Returns

	HCAT	US Healthcare Services	US Market
7D	-10.8%	-3.4%	-2.5%
1Y	-72.8%	-38.7%	-21.2%

Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned -40.4% over the past year.

Return vs Market: HCAT underperformed the US Market which returned -21.7% over the past year.

Price Volatility

Is HCAT's price volatile compared to industry and market?
HCAT volatility
HCAT Average Weekly Movement	12.5%
Healthcare Services Industry Average Movement	12.7%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: HCAT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: HCAT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2008	1,200	Dan Burton	https://www.healthcatalyst.com

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017.

Health Catalyst Fundamentals Summary

How do Health Catalyst's earnings and revenue compare to its market cap?
HCAT fundamental statistics
Market Cap	US$834.45m
Earnings (TTM)	-US$147.30m
Revenue (TTM)	US$254.17m

3.3x

P/S Ratio

-5.7x

P/E Ratio

Is HCAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
HCAT income statement (TTM)
Revenue	US$254.17m
Cost of Revenue	US$130.50m
Gross Profit	US$123.67m
Other Expenses	US$270.97m
Earnings	-US$147.30m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.72
Gross Margin	48.66%
Net Profit Margin	-57.95%
Debt/Equity Ratio	46.9%

How did HCAT perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is HCAT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HCAT?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for HCAT. This is calculated by dividing HCAT's market cap by their current preferred multiple.
What is HCAT's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$834.45m

HCAT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.6x
Enterprise Value/EBITDA	-7.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HCAT's PS Ratio compare to its peers?

HCAT PS Ratio vs Peers

The above table shows the PS ratio for HCAT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	7.5x
SLP Simulations Plus	20.2x	17.8%	US$1.0b
PHR Phreesia	5.8x	25.4%	US$1.3b
NXGN NextGen Healthcare	2x	6.1%	US$1.2b
CNVY Convey Health Solutions Holdings	2.2x	13.8%	US$762.0m
HCAT Health Catalyst	3.3x	16.0%	US$834.4m

Forward PS

Price-To-Sales vs Peers: HCAT is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (7.5x).

Price to Earnings Ratio vs Industry

How does HCAT's PE Ratio compare vs other companies in the US Healthcare Services Industry?

Price-To-Sales vs Industry: HCAT is expensive based on its Price-To-Sales Ratio (3.3x) compared to the US Healthcare Services industry average (3.1x)

Price to Sales Ratio vs Fair Ratio

What is HCAT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HCAT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.3x
Fair PS Ratio	3x

Price-To-Sales vs Fair Ratio: HCAT is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (3x).

Share Price vs Fair Value

What is the Fair Price of HCAT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HCAT's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Health Catalyst forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

5.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HCAT's revenue (16% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: HCAT's revenue (16% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCAT is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Health Catalyst performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

4.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HCAT is currently unprofitable.

Growing Profit Margin: HCAT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: HCAT is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare HCAT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HCAT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).

Return on Equity

High ROE: HCAT has a negative Return on Equity (-30.63%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Health Catalyst's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: HCAT's short term assets ($482.5M) exceed its short term liabilities ($92.7M).

Long Term Liabilities: HCAT's short term assets ($482.5M) exceed its long term liabilities ($251.4M).

Debt to Equity History and Analysis

Debt Level: HCAT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if HCAT's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HCAT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: HCAT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.2% each year

Discover healthy companies

Dividend

What is Health Catalyst current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate HCAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HCAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HCAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HCAT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HCAT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure

CEO

Dan Burton (47 yo)

9.67yrs

Tenure

US$5,961,043

Compensation

Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...

CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD5.96M) is above average for companies of similar size in the US market ($USD4.03M).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: HCAT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: HCAT's board of directors are considered experienced (5.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/07/01 00:00
End of Day Share Price	2022/07/01 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31